Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-Daily Adefovir, Didanosine, Efavirenz, and Lamivudine for HIV
NCT00002234Phase 2Completed
- Sponsor
- Gilead Sciences
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adefovir dipivoxil in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Primary endpoints: Plasma HIV-1 RNA at 48 weeks and Lymphocyte Subsets at 48 weeks. Status: completed.
02
Drugs
adefovir dipivoxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002234.